In addition, nilotinib also promoted erythroid differentiation and GATA1 accumulation in K562 cells upon inhibition of RNA polymerase I. Since nilotinib (Tasigna) is an FDA/EMA‐approved drug for the treatment of chronic myeloid leukemia, it is attractive for repurposing in the treatment of DBA and other ribosomopathies. The gene discussed is GATA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.